Industry Recommendations on Evaluating OTC Consumer Behavior Douglas Ws. Bierer, Ph.D. Consumer Healthcare Products Association.

Slides:



Advertisements
Similar presentations
Nursing Diagnosis: Definition
Advertisements

THE JOINT COMMISSION PATIENT BLOOD MANAGEMENT PERFORMANCE MEASURES
The Statisticians Role in Pharmaceutical Development
1. Session structure Overview Definition & examples Actions Outputs Challenges Exercises Module 4 Control measures & risk reassessment 2.
ACGME Survey and Program Evaluation Analysis
Establish Verification Procedures (Task 11 / Principle 6)
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Proprietary Name Testing Using “Prescription Analysis Studies” Thomas H. Hassall, MS Director, Global Regulatory Policy Merck Research Laboratories.
Good Clinical Practice GCP
Driving Home the Point: Medicines, Impaired Driving, and You Ali Mohamadi, MD Medical Officer Professional Affairs and Stakeholder Engagement RADD-ONDCP.
Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.
Leadership Competencies: Developing Success for the Future By Eugene P. Buccini, Ph.D.
Committee Questions Design, Statistical Considerations and Study Conduct 1. There are no clear guidelines regarding the number of people that should be.
The Audit Process Tahera Chaudry March Clinical audit A quality improvement process that seeks to improve patient care and outcomes through systematic.
Life Sciences Research Office (LSRO) Evaluating Adverse Event Reporting Systems for Dietary Supplements January 30-31, 2003 “Open Portion of Meeting”
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
Process Skill demonstrate safe practices during laboratory and field investigations, including chemical, electrical, and fire safety, and safe handling.
CHPA Comments on Efficacy and Labeling Issues for OTC Drug Products Used in the Treatment of Tinea Pedis CHPA Antifungal Task Group 6 May 2004.
DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.
1 Nonprescription Drugs and Dermatologic and Ophthalmic Drugs Joint Advisory Committee Meeting Over-the-Counter Antifungal Drug Products Treatment of Tinea.
Survey of Medical Informatics CS 493 – Fall 2004 November 8, 2004 V. “Juggy” Jagannathan.
Important informations
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Reasonable Accommodation and TEAP Andrew Berger, Ph.D., Region 6 Mental Health Consultant National Wellness Conference April 26, 2001.
Implications of the Current State of Scientific Knowledge David W K Acheson, M.D. Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration.
Behavioral Studies Supporting Rx-to-OTC Switches Saul Shiffman, Ph.D. Professor, Psychology, Psychiatry & Pharmaceutical Sciences, University of Pittsburgh.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
SELECT Label Comprehension Studies Mevacor™ Daily Capt. Laura Shay, RN, MS, C-ANP Division of Nonprescription Clinical Evaluation Center for Drug Evaluation.
Mevacor 20 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees December 13, 2007 Andrea Leonard-Segal, M.D.
A “PHILOSOPHICAL” APPLICATION THE SCIENTIFIC METHOD:
Welcome to Workshop #5: Accelerated Approval (AA) in Rare Diseases: Review of a White Paper Proposal Emil D. Kakkis, M.D., Ph.D. President and Founder.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Basic Nursing: Foundations of Skills & Concepts Chapter 9
Focused Assessment A Risk Based Approach to Audit Office of Strategic Trade Regulatory Audit Division.
1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,
how many people in the community need your services? where is the greatest need in your service area? why serve this population not that one? where should.
Label Comprehension, Self-Selection & Actual Use Studies: Issues & Challenges Nonprescription Drugs Advisory Committee September 25, 2006 Andrea Leonard-Segal,
United States Department of Agriculture Food Safety and Inspection Service Using Risk to Direct In-Plant Processing and Off-line Slaughter Inspection Activities.
Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.
Standard 10: Preventing Falls and Harm from Falls Accrediting Agencies Surveyor Workshop, 13 August 2012.
Prilosec1 ® 20 mg Tablets Rx to OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products (HFD-560) Food and Drug Administration 1.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
© 2009 Concentrics Research LLC Consumer Comprehension & Outcomes Research Risk Communication Advisory Committee Julie L. Aker President & CEO Concentrics.
1 Presentation of the Pharmaceutical Research and Manufacturers of America at FDA Part 15 Hearing on Communication of Drug Safety Information December.
Evaluating Consumer Comprehension of Prescription Drug Information Saul Shiffman, Ph.D. Senior Scientific Advisor, Pinney Associates Consulting to industry.
© 2006 Concentrics Research LLC Switch Challenges and Suggested Solutions Julie L. Aker President & CEO Concentrics Research.
Continual Service Improvement Methods & Techniques.
Consumer and Provider Education and Engagement Breakout Session Betsy Abramson, Wisconsin Coalition Against Domestic Violence Alison Bergum, UW Population.
Pivotal Label Comprehension Study Mevacor™ OTC Capt. Laura Shay, RN, MS, C-ANP Division of Over-the-Counter Drug Products Center for Drug Evaluation and.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.
1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.
ADVISORY BOARD ON RADIATION AND WORKER HEALTH. HISTORY u FORMED IN 2001 u PRESIDENTIAL APPOINTMENTS u BALANCE OF SCIENTIFIC, MEDICAL, AND WORKER PERSPECTIVES.
Safety Management Systems Session Four Safety Promotion APTA Webinar June 9, 2016.
GCP (GOOD CLINICAL PRACTISE)
1 Improving the agenda for SWITCH for nonprescription Medicines Sheila Kelly WSMI September 2015.
Nursing Process n116. The Nursing Process  Assessment  Diagnosis  Planning  Implementing  Evaluating.

Karen Proud, President Consumer Health Products Canada
Presenter: Christi Melendez, RN, CPHQ
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Critical Decision Points in Insomnia
Designing Effective Printed Educational Materials
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Industry Recommendations on Evaluating OTC Consumer Behavior Douglas Ws. Bierer, Ph.D. Consumer Healthcare Products Association

Industry/FDA History on Consumer Behavior Research  CHPA Regulatory and Scientific Conference workshops  Consumer Behavior Roundtable – 2005  Points-to-Consider Document

Recommendations for Evaluating Consumer Behavior Decisions about whether consumer behavior is “acceptable” should be based on actual risk to consumer

When Evaluating Consumer Behavior  No magic overall number for success/failure  All non-compliance is not the same  An “incorrect” response may be an appropriate behavior

No “Magic Number”  Risk of non-compliance not the same for all label statements  Each label statement/drug must be analyzed separately  No one overall number of acceptance

All Non-Compliance Not The Same  Non-compliance dosing w/low tox drug ≠ non-compliance w/contraindicated drug  Evaluation of consumer behavior based on consumer risk

An “Incorrect” Response May Be An Appropriate Behavior  Response may be benefit/risk decision  Need to understand thought process  Must consider medical significance of “incorrect answer/action”  “Talk to doctor” should not be incorrect in self-selection studies

Recommendations  Pre-define OTC label elements critical to safe use  Focus on the basis for consumer decisions  Consider wide variety of real-world consumer behavior data

Pre-Define OTC Label Elements  Risks are captured in OTC labeling Based on Rx use history Consumer behaviors that may lead to potential risk  Predefine label elements critical for safe use in an OTC setting

Focus on Understanding Consumer Decisions  Understand basis for consumer decision  Self-reported information is valid  OTC drugs should be approved if: Risk of non-compliance to critical label elements is low Lack of intermediary doesn’t present an additional risk to the consumer

Must Consider Real-World Consumer Behavior Data  Consumer habits and practices  Consumer surveys  In-market use patterns  Targeted educational programs

Remarkable OTC Safety Record  >25 Rx-to-OTC switches approved --in part on consumer behavior data  Consistent record of overall safety  No products removed

Summary Evaluating whether consumer behavior is “acceptable” should be based on actual risk to consumer